The event aims to promote the visibility of the NAATTC and its activities so far, foster engagement with the wider Advanced Therapy (AT) community and share best practice. There will be a reflection on challenges of AT delivery, learning points and plans for the future, tracking the pathway of AT development and implementation with a focus on CAR T-cell treatments.

After a warm welcome and introduction from a member of the NAATTC Executive board, followed by a plenary speaker, there will then be a series of breakout sessions hosted by key stakeholders involved in the Advanced Therapy delivery journey including:

• Reflections on CAR T Delivery in the NHS- Dr Tobias Menne, The Newcastle upon Tyne Hospitals NHS Foundation Trust

• An Industry Perspective on Advanced Therapy Delivery in the NHS- Chris Vann, Autolus Therapeutics

• JACIE Inspection Process- Dr Erin Hurst, The Newcastle upon Tyne Hospitals NHS Foundation Trust
  

• Safety Considerations/ ITU Capacity- Dr SuzanneO'Neill, The Newcastle upon Tyne Hospitals NHS Foundation Trust

• Regulatory Perspective- Advanced Therapy Commissioning- Dr William Horsley, North of England Specialist Commissioning Team

• Genetic Modification Safety Committee Considerations for Advanced Therapies- Dr Sheila Waugh, The Newcastle upon Tyne Hospitals NHS Foundation Trust

• Institutional Readiness for Advanced Therapies - Professor Andrew Webster, University of York

• Advanced Therapy Medicinal Product and Medicines Governance- Anne Black, Newcastle upon Tyne Hospitals NHS Foundation

• Commissioning for Advanced Therapy Medicinal Produsts the NHS England Perspective- Steve Williamson, NHS England

• Scottish Medicines Consortium Requirements for Advanced Therapy Medicinal Product Provision-Dr Alan MacDonald, Scottish Medicines Consortium

• Supply Chain Considerations for Advanced Therapies- Alan Runacus, World Courier

• Reimbursement Considerations for Advanced Therapy Medicinal Products- Dr Panos Kefalas, The Cell and Gene Therapy Catapult

The event will be of interest to those working in the following fields:

• Regulatory agencies (SMC, NICE, NHS England)

• Representatives for PPI groups

• Pan Advanced Therapy Treatment Centre (ATTC) Network

• Wider Northern Alliance community (Clinicians, clinical delivery staff, wider research community)

• Charities

• Industry

• Academia
  

For further information please contact: NAATTC@nuth.nhs.uk